Fulvestrant treatment, as well as knockdown of the ERα gene, reduced the growth of tamoxifen-resistant breast cancer cells; moreover, this strategy was efficacious in several xenograft experiments [7, 46, 47]. This evidence concerns the gene ESR1 and breast carcinoma.